Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

November 18, 2022 by Alan Khadavi

Xolair for idiopathic angioedema

Xolair for idiopathic angioedema may be used as treatment for patients who are suffering from uncontrolled swelling. Currently Xolair is approved for chronic idiopathic urticaria. But the underlying disease mechanism of chronic hives is similar to idiopathic angioedema.

Omalizumab (Xolair) for treating Angioedema and Chronic Hives

Xolair for Idiopathic Anaphylaxis

Angioedema is defined as recurrent episodes of swelling of the deep dermis affecting the skin, GI tract and respiratory tissue. This accounts for nearly 100,000 ER visits a year in the US during which no causative agent is found. Idiopathic angioedema refers to episodes of angioedema without hives for which no explanation can be found despite a thorough investigation. Antihistamines have been found to help decrease symptoms in some patients.

Xolair is a recombinant, humanized IgG1 monoclonal antibody that binds to free IgE, preventing its binding to the high-affinity IgE receptor and reduces the receptor density on mast cells, basophils and dendritic cells. It was approved in 2014 by the FDA for patients who failed using antithistamines for chronic hives. Many patients who do have chronic hives also have symptoms of angioedema.

FDA approves Xolair for Chronic Urticaria

Xolair has been proposed for Idiopathic Angioedema. A recent study published in the Annals of Allergy, Asthma and Immunology titled “Omalizumab for treatment of idiopathic angiodema” looked to see if this treatment was effective. The study showed greater improvements with Xolair in the Angioedema Activity Score, Visual Analogue Scale, Angioedema Quality of Life Questionnaire and number of angioedema episodes per month in patients who received omalizumab vs. placebo.

In this 24 week treatment period, this study provides evidence that Xolair improves Idiopathic Angioedema. Xolair may serve as a viable diagnostic and therapeutic option for patients with idiopathic angioedema.

Anaphylaxis with Xolair, a Case Study

Xolair (Omalizumab) for Chronic Urticaria

Idiopathic Angioedema

New Treatment for Hives being studied

Update June 13, 2024

“Omalizumab for treatment of idiopathic angioedema” was published in the Annals of Allergy, Asthma and Immunology, the study showed that Xolair may be a reasonable step up therapy after a trial of high dose antihistamines, as it led to improvements in angioedema symptom scores. Decreases in the frequency and duration of angioedema episodes and decrease in medication use were also seen.  There was significant improvement in the AAS7 (Angioedema Activity Score for 7 days), with Xolair. Patients received 300mg of Xolair every 4 weeks for 6 months in the study.

 

Filed Under: biologics, Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page